Home » Sepsis: A critical healthcare burden needing rapid diagnoses to improve patient outcomes
Sepsis: A critical healthcare burden needing rapid diagnoses to improve patient outcomes
Presented by Demi-Colton
The mortality rate of sepsis patients increases by as much as 8% each hour proper treatment is not started. Sepsis costs the US healthcare system $62 billion and leads to 270,000 deaths annually. Current diagnoses are inadequate – they take too long and sepsis patients do not have time. Furthermore, they are often wrong. This discussion will focus on the burden of sepsis and how we need to change the paradigm.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
A recent article in @NatureMicrobiol highlights the importance of tests like #T2Candida and how they may enable early diagnosis of fungal infections, which lead to "faster initiation of appropriate treatment and improved survival rates."